Loading

Lilly Halts Development of Semagacestat for Alzheimer’s Disease

Eli Lilly and Company (NYSE: LLY) will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer’s disease,

Original Source of Lilly Halts Development of Semagacestat for Alzheimer’s Disease

Add this post to your favorites social bookmark

Bookmark and Share